免疫检查点抑制剂在肺肉瘤样癌中的疗效
该回顾性研究纳入37例中心确诊的肺肉瘤样癌患者,接受免疫检查点抑制剂作为二线及以上治疗。客观缓解率40.5%,疾病控制率64.8%,中位总生存12.7个月。PD-L1状态不影响缓解,高TMB者占87.5%,支持前瞻性研究免疫检查点抑制剂用于一线治疗。
要点
- 肺肉瘤样癌二线及以上免疫治疗客观缓解率40.5%,疾病控制率64.8%。
- 中位总生存12.7个月,约三分之一患者出现早期进展。
- PD-L1状态不影响缓解,高TMB者占87.5%,缓解者TMB有更高趋势。
核心结论
- 肺肉瘤样癌患者接受免疫检查点抑制剂治疗呈现高缓解率和延长的总生存。
- 数据支持在肺肉瘤样癌一线治疗中前瞻性研究免疫检查点抑制剂。
研究设计与样本
- 回顾性研究纳入2011至2017年中心确诊的37例肺肉瘤样癌患者,接受免疫检查点抑制剂作为二线及以上治疗。
- PD-L1表达用免疫组化SP263克隆评估,TMB用Foundation One panel评估,TMB≥10突变/兆碱基定义为高。
主要发现
- 客观缓解率40.5%,疾病控制率64.8%,不依赖于PD-L1状态。
- 中位总生存12.7个月(范围0.3-45.7),三分之一患者出现早期进展。
- PD-L1中位表达70%(0-100),缓解者PD-L1有更高趋势,PD-L1阳性者客观缓解率58.8%,唯一PD-L1阴性者0%(p=0.44)。
- TMB中位18(4-39)突变/兆碱基,87.5%病例为高TMB,缓解者对比稳定或进展者TMB有更高趋势(p=0.2)。
关键数值与推荐
- TMB高定义为≥10突变/兆碱基,87.5%病例为高TMB。
- 免疫治疗以纳武利尤单抗为主(86.5%),二线治疗占54%,三线及以上占46%。
临床怎么用
- 肺肉瘤样癌二线及以上可考虑免疫检查点抑制剂治疗,需关注约三分之一早期进展风险。
- PD-L1状态不影响缓解判断,高TMB常见但TMB与缓解趋势未达统计学显著。
局限性
- 回顾性研究,样本量小(37例),PD-L1与TMB分析未达统计学显著。
- 免疫治疗以纳武利尤单抗为主,其他免疫检查点抑制剂数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immune checkpoint inhibitors (ICIs) have improved cancer prognosis but have not been evaluated specifically in sarcomatoid carcinoma (SC), a rare lung cancer subtype with poor prognosis. As such, our study sought to retrospectively assess the efficacy of ICI in SC. METHODS: All consecutive patients with centrally confirmed SC treated using ICI as a second-line treatment or beyond between 2011 and 2017 were enrolled. Programmed death-ligand 1 (PD-L1) tumor expression was assessed using immunohistochemistry (SP263 clone) and the tumor mutational burden (TMB) with the Foundation One panel. TMB was considered high if it was greater than or equal to 10 mutations per megabase. RESULTS: Overall, 37 patients with SC were evaluated, predominantly men (73%) with a median age of 63.2 years (36.8-79.7) and who were current or former smokers (94.6%). Immunotherapy (nivolumab, 86.5% of cases) was given as a second-line treatment in 54% of the patients and as third-line treatment or beyond in 46% of the patients. The objective response rate was 40.5% and disease control rate was 64.8%, regardless of PD-L1 status. Median overall survival was 12.7 months (range: 0.3-45.7). One-third of patients exhibited early progression. The median PD-L1 expression was 70% (0-100). There was a trend toward higher PD-L1 expression in responsive diseases, with an objective response rate of 58.8% in patients with PD-L1+ and 0% in the one patient with PD-L1- (p = 0.44). The median TMB was 18 (4-39) mutations per megabase, with 87.5% of the cases displaying a high TMB. There was a trend toward higher TMB in responders versus stable or progressive diseases (p = 0.2). CONCLUSIONS: Patients with SC exhibited high response rates and prolonged overall survival under ICI treatment. These data support the prospective investigation of ICI in patients with SC who are under first-line treatment.
引用
- Domblides C, Leroy K, Monnet I, et al. Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma. J Thorac Oncol. 2020. PMID: 31991225. doi:10.1016/j.jtho.2020.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。